References
- Basarab GS, Barvian K, Beaudoin M-E, et al. (2013). Novel DNA gyrase inhibiting antibacterial agents: fusion of a benzisoxazole with a spirocyclic octahydropyrido-oxazine pyrimidinetrione. ICAAC F1–1129
- Berger JM, Gamblin SJ, Harrison SC, Wang JC. (1996). Structure and mechanism of DNA topoisomerase II. Nature 379:225–32
- Bryskier A. (1993). Fluoroquinolones: mechanisms of action and resistance. Int J Antimicrob Agents 2:151–83
- Collin F, Karkare S, Maxwell A. (2011). Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. Appl Microbiol Biotechnol 92:479–97
- Dalhoff A. (2012). Global fluoroquinolone resistance epidemiology and implictions for clinical use. Interdiscip Perspect Infect Dis 2012:976273 (1--37)
- Hooper DC. (2001). Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 7:337–41
- Huband MD, Cohen MA, Zurack M, et al. (2007). In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. Antimicrob Agents Chemother 51:1191–201
- Kitamura S, Sugihara K, Kuwasako M, Tatsumi K. (1997). The role of mammalian intestinal bacteria in the reductive metabolism of zonisamide. J Pharm Pharmacol 49:253–6
- Mannens G, Huang ML, Meuldermans W, et al. (1993). Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 21:1134–41
- Maruri F, Sterling TR, Kaiga AW, et al. (2012). A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 67:819–31
- Miller AA, Bundy GL, Mott JE, et al. (2008). Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors. Antimicrob Agents Chemother 52:2806–12
- Ruble CJ, Hurd AR, Johnson TA, et al. (2009). Synthesis of (-)-PNU-286607 by asymmetric cyclization of alkylidene barbiturates. J Am Chem Soc 131:3991–7
- Sanyal G, Doig P. (2012). Bacterial DNA replication enzymes as targets for antibacterial drug discovery. Expert Opin Drug Discov 7:327–39
- Shigemura K, Tanaka K, Yamamichi F, et al. (2012). Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections? A statistical analysis study. Int J Antimicrob Agents 40:516–20
- Sousa T, Paterson R, Moore V, et al. (2008). The gastrointestinal microbiota as a site for the biotransformation of drugs. Int J Pharm 363:1–20